Tag: fiscal

WOODLAND PARK, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) announced today that it will hold a conference call on Wednesday, August 13, 2025, at 9:00 a.m. ET. Anterix senior management, led by President and CEO Scott Lang, will discuss the Company's first quarter fiscal 2026 results. A press release regarding the results will be issued after the close of the market on Tuesday, August 12, 2025.

GREAT NECK, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that its total revenues for the three months ended June 30, 2025 were approximately $2,355,000, compared to approximately $2,443,000 for the three months ended June 30, 2024, a decrease of $88,000, or 3.6%. The decrease in revenue was primarily attributable to lower interest income, resulting from a reduction in loans receivable, period-over-period, partially offset by an increase of origination fees. For the three months ended June 30, 2025 and 2024, approximately $1,899,000 and $2,033,000, respectively, of the Company’s revenues were attributable to interest income on secured commercial loans that the Company offered to real estate investors, and approximately $456,000 and $411,000, respectively, of its revenues were attributable to origination fees on such loans. The loans are principally secured by collateral consisting of real estate and accompanied by personal guarantees from the principals of the borrowers.

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI^® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- CSW Industrials, Inc. (NYSE: CSW) announced that it will release its earnings results for the fiscal first quarter ended June 30, 2025, on Thursday, July 31, 2025, before the market opens. The Company will host a conference call the same day at 10:00 am Eastern Time to discuss the results.

New York, N.Y., July 21, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced it will host its third fiscal quarter financial results and business update webcast on Thursday, August 14, 2025, at 5:00 p.m. ET.